Viskase Q2 2026: Going Concern Warning as Losses Mount and Cash Dwindles
Summary
Viskase's Q2 2026 10-Q includes a going concern warning, a $27.5 million operating cash burn, and only $7.9 million in cash. The company must refinance its credit facility by August 2027 to survive.
Key Events · Earnings and Guidance · ENZN
-
Going Concern Warning
Substantial doubt exists about Viskase's ability to continue as a going concern. The company must refinance its Senior Credit Facility before its August 2027 maturity, and there is no assurance it can obtain sufficient funds on satisfactory terms.
-
Operating Cash Burn of $27.5M
Net cash used in operating activities was $27.5 million for the six months ended June 30, 2026, a sharp reversal from $2.4 million provided in the prior year period, driven by increases in receivables, inventories, and other current assets.
-
Revenue Decline of 7.7%
Net sales fell to $176.7 million for the first half of 2026, down from $191.5 million a year ago, primarily due to volume decreases from temporary production capacity issues related to the 2025 plant closure.
-
Liquidity Squeeze
Cash and equivalents stood at just $7.9 million at June 30, 2026, with only $5.8 million in unused borrowing capacity under the amended credit facility. The company also has $129.4 million in total debt.
Analysis · ENZN · Life Sciences
Viskase's 10-Q reveals a going concern warning — substantial doubt exists about its ability to continue without refinancing its Senior Credit Facility by August 2027. The company burned $27.5 million in cash from operations in the first half of 2026, leaving only $7.9 million in cash. Revenue fell 7.7% due to temporary capacity constraints from a plant closure, and the net loss, while improved from last year, remains significant at $11.9 million. The credit facility was amended to extend maturity to August 2027, but at a higher interest rate, and the company has just $5.8 million in unused borrowing capacity. The stock also transitioned to the OTCID marketplace under a new symbol, VISK, on July 23, 2026. This filing fundamentally alters the risk profile — survival is now contingent on a refinancing that is not assured.
At the time of this filing, ENZN was trading at $4.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $62.3M. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.